Indication
Chronic Obstructive Pulmonary Disease
The Chronic Obstructive Pulmonary Disease pipeline: 44 tracked drugs, 13 approved for this indication.
13 approved / phase 48 Phase 316 Phase 21 Phase 1/25 Phase 11 preclinical / unstaged
Compare the share prices of listed companies in Chronic Obstructive Pulmonary Disease →
Total attributable cost
$48.0B
$4,322/patient
Drug spend
$20.9B
$1,887/patient
44% of total cost is drugs
All severities, diagnosed (2022 estimate) · US